Straits Times Index
3,323.20 -6.89 (-0.21%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
67,882.27 -396.30 (-0.58%) CMC Crypto 200
1,458.53 -26.17 (-1.76%)
VERU Oct 2024 0.500 call
| Previous close | 0.3900 |
| Open | 0.3900 |
| Bid | 0.3200 |
| Ask | 1.3100 |
| Strike | 0.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.3900 - 0.3900 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
Simply Wall St.Individual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%
Key Insights Veru's significant individual investors ownership suggests that the key decisions are influenced by...
GlobeNewswireVeru to Present at the Jefferies Global Healthcare Conference
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru’s Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss whe
- GlobeNewswire
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator f
